Neuland Laboratories Limited

NSE NEULANDLAB.NS

Neuland Laboratories Limited Price to Earnings Ratio (P/E) on January 14, 2025: 55.12

Neuland Laboratories Limited Price to Earnings Ratio (P/E) is 55.12 on January 14, 2025, a 25.48% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Neuland Laboratories Limited 52-week high Price to Earnings Ratio (P/E) is 76.80 on December 06, 2024, which is 39.34% above the current Price to Earnings Ratio (P/E).
  • Neuland Laboratories Limited 52-week low Price to Earnings Ratio (P/E) is 25.76 on June 04, 2024, which is -53.26% below the current Price to Earnings Ratio (P/E).
  • Neuland Laboratories Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 47.01.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
NSE: NEULANDLAB.NS

Neuland Laboratories Limited

CEO Mr. Davuluri Sucheth Rao
IPO Date Oct. 13, 2008
Location India
Headquarters Phoenix IVY Building
Employees 1,643
Sector Health Care
Industries
Pharmaceuticals
Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

StockViz Staff

January 15, 2025

Any question? Send us an email